About Metagenomi
Metagenomi focuses on developing new genome editing tools for genetic medicine. The company explores natural environments to find undiscovered genetic material, which is then sequenced and engineered into potential therapeutics. By utilizing artificial intelligence and high-throughput screening, Metagenomi can quickly analyze billions of proteins to identify effective genome editing tools. This approach sets them apart from competitors who may not leverage such advanced technologies. The goal of Metagenomi is to create curative treatments for diseases through gene editing, aiming to significantly impact healthcare providers and patients.
Emeryville, CaliforniaHeadquarters
2016Year Founded
$366.1MTotal Funding
IPOCompany Stage
AI & Machine Learning, Biotechnology, HealthcareIndustries
201-500Employees
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Performance Bonus
Stock Options
Risks
Class action lawsuits could lead to financial liabilities and damage Metagenomi's reputation.
The termination of the Moderna partnership may impact Metagenomi's financial projections.
Lack of clinical-stage candidates contributed to a 31% drop in Metagenomi's stock price.
Differentiation
Metagenomi uses metagenomics and AI to discover novel genome editing systems.
The company sources genetic material from unexplored natural environments for unique discoveries.
Metagenomi's gene editing systems are ultra-small, efficient, and have reduced immune response risks.
Upsides
Increased interest in metagenomics is driving investment in companies like Metagenomi.
The trend towards personalized medicine boosts demand for precise genome editing tools.
Metagenomi's partnership with Ionis could potentially lead to a $3 billion deal.
Funding
Total raised$366.11 M
Latest valuation$875.00 M
StageIPO
IPO
1/31/2024$94
SERIES B
12/31/2022- Novo Holdings
- Pura Vida Investments
- Bristol-Myers Squibb
- Irving Investors
- SymBiosis
- Moderna Therapeutics
- Eventide Asset Management
- Frazier Healthcare Partners
- Surveyor Capital
- Leaps by Bayer
- RA Capital Management
- Marshall Wace
- Humboldt Fund
- Farallon Capital Management
- Deep Track Capital
- PFM Health Sciences
- Catalio Capital Management
- Millennium Management
$100
$875.00 MSERIES A
3/31/2021$10
$325.00 M